Barbara G. Utterback

Author

Eli Lilly (United States)

Also Known As

Barbara G Utterback, Barbara G. Utterback, Barbara Utterback

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Université Paris Cité Hôpital Cochin Cliniques Universitaires Saint-Luc Assistance Publique – Hôpitaux de Paris

About

Barbara G. Utterback is an author at Eli Lilly (United States) specializing in natural sciences, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	321
2	Natural Sciences	7	7	176
3	Biochemistry	7	7	176
4	Chemical Biology	4	4	141
5	Critical Care Medicine	1	1	156

Barbara G. Utterback

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death Edward Abraham, Pierre‐François Laterre, Rekha Garg, New England Journal of Medicine	2005	882
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] Gary T. Kinasewitz, S. Betty Yan, Bruce R. Basson, Critical Care	2004	362
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications Rolf M. Mesters, Jeff Helterbrand, Barbara G. Utterback, Critical Care Medicine	2000	202
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial Jean-François Dhainaut, Pierre‐François Laterre, Jonathan Janes, Intensive Care Medicine Critical Care MedicineSevere Sepsis PatientsProwess TrialClinical TherapeuticSepsis	2003	156
Differential Activation of Cytosolic Phospholipase A2 (cPLA2) by Thrombin and Thrombin Receptor Agonist Peptide in Human Platelets. EVIDENCE FOR ACTIVATION OF cPLA2 INDEPENDENT OF THE MITOGEN-ACTIVATED PROTEIN KINASES ERK1/2 Ruth M. Kramer, Edda F. Roberts, Paul A. Hyslop, Journal of Biological Chemistry	1995	125
Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis Phil Barton, André C. Kalil, Simon Nadel, PEDIATRICS	2004	125
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* Jean-François Dhainaut, Pierre-François Laterre, Steven P. LaRosa, Critical Care Medicine	2003	92
ENHANCE: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis* Brahm Goldstein, Simon Nadel, Mark Peters, Pediatric Critical Care Medicine	2006	63
Dibasic Benzo[<i>b</i>]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure−Activity Relationships, and Binding Orientation Daniel J. Sall, Jolie Bastian, John A. Buben, Journal of Medicinal Chemistry Pharmaceutical ScienceAltmetric Attention ScorePharmacotherapyChemical BiologyPharmaceutical Chemistry	1997	54
Non-Peptide RGD Surrogates Which Mimic a Gly-Asp β-Turn: Potent Antagonists of Platelet Glycoprotein IIb−IIIa Matthew J. Fisher, Bruce P. Gunn, Cathy S. Harms, Journal of Medicinal Chemistry Chemical BiologyType IiPlatelet Receptor Gpiib-iiiaMolecular PharmacologyThrombosis	1997	49

Page 1